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The recombinant Kunitz protease inhibitor module (domain CS) of human collagen a3(VI) chain was 
previously shown to lack inhibitory activity for proteases with trypsin-like specificity and some other 
proteases. We have now prepared mutants in the binding loop region including the PI’ site (D2889+A), 
the P2’ site (F2890-R) and the P3 site (T2886+P) and in a more remote region (W2907-V) either 
as individual substitutions or combinations of them. These mutants were analyzed for their kinetics of 
binding to trypsin by surface plasmon resonance and for their capacity to inhibit various proteases. Single 
substitutions (D+A, T+P, W+V) showed an effect only for D+A which bound to trypsin with Kc, = 
0.25 pM. A 25-100-fold increase in affinity was observed for the double mutants T + P / D - + A  and 
F+WD+A and approached the affinity of aprotinin ( K d  ~ 0 . 0 1  nhI) in two different triple mutants. 
These affinities correlated well with the inhibitory capacities of the mutants for trypsin in the cleavage 
of a large protein and a small peptide substrate. A similar but not completely identical improvement in 
inhibitory capacity was also observed for leucocyte elastase but not for thrombin. These data could be 
interpreted in terms of steric interferences or lack of hydrogen bonding of a few critical residues based 
on three-dimensional structures available for the CS domain. 
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The SO-60-residue Kunitz-type module is not only charac- 
teristic for a distinct family of protease inhibitors (Bode and 
Huber, 1992) but also found in larger proteins such as in a neural 
amyloid precursor protein (Ponte et al., 1988; Tanzi et al., 1988; 
Kitaguchi et al., 1988) and at the C-terminals of collagen rx3(VI) 
chain (Bonaldo and Colombatti, 1989; Chu et al., 1990) and 
nl(VI1) chain (Greenspan, 1993). The sequences of the amyloid 
precursor module and the a3(VI) chain module contained an ar- 
ginine at the PI equivalent position of the binding loop indicat- 
ing their potential to inhibit trypsin or trypsin-like proteases. 
This prediction was confirmed for the amyloid protein domain 
in several recombinant studies (Oltersdorf et al., 1989: Kido et 
al., 1990: Castro et al., 1990; Wagner et al., 1992; Oyama et 
al., 1993: van Nostrand et al., 1994). A recombinant Kunitz- 
type module of a3(VI) chain (domain CS, see Chu et al., 1990). 
however, failed to show any inhibitory activity for trypsin, 
thrombin, kallikrein, leucocyte elastase and mast-cell chymase 
(Mayer et al., 1994). This failure was thought to be due to the 
presence of unfavorable residues in the binding loop (P3, PI’ 
positions) as well as in the first strand of the core domain of 
the module. Recent studies by NMR (Zweckstetter et al., 1996) 
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and by X-ray crystallography (Arnoux et al., 199S), however, 
demonstrated for the recombinant domain C5 a secondary and 
tertiary structure very close to that of the same module of 
various protease inhibitors (Bode and Huber, 1992) and of the 
amyloid precursor (Hynes et al., 1990). 
These observations indicated that domain CS could be a suit- 
able scaffold for studying structure/function relationships of 
such modules by subtle variation of the amino acid sequence. In  
the present study we have addressed this question by targeted 
mutagenesis of just four residues of domain CS using the trypsin 
inhibitor aprotinin as a lead structure for designing the substitu- 
tions. The data demonstrated no or only small effects of single 
substitutions but dramatic changes after introducing three substi- 
tutions in two different combinations. These two triple mutants 
were in fact indistinguishable from bovine aprotinin with respect 
to their binding affinity and inhibitory capacity for trypsin. 
Furthermore, several of the effects could be explained at the 
level of the solution structure of domain C5 which was available 
through NMR studies (Zweckstetter et al., 1996). 
MATERIALS AND METHODS 
Construction of an episomal expression vector for do- 
main C5. The eukaryotic episomal expression vector pCEP4 
(10.4 kb, Invitrogen) wa\ used to  produce a modified vector 
pCEP-Sh (9.23 kb) in order to replace the hygromycin by the 
phleomycin resistance gene to allow selection both in bacteria 
and mammalian cells. An 8.2-kb fragment containing the cyto- 
megalovirus (CMV) promoter was generated from pCEP4 by 
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restriction with NruI and partial cleavage with SalI for the selec- 
tive release of the hygromycin resistence gene. A 989-bp HpaI- 
RumHI fragment of the PUT 626 vector (Eurogentech) contain- 
ing the SV40 and EM7 promoters, the phleomycin resistance 
gene (Sh-ble) and the SV40 poly-(A) signal was inserted into 
the pCEP4 fragment by blunt end ligation at one site (NruI) and 
the use of an annealed 16 bp adaptor (5’-TCGAGGAAGCGGT- 
TCG and S’GATCCGAACCCCTTCC) for connection of the 
SulI and BumHI sites. This novel pCEP-Sh vector was cloned 
in Escherichin coli on Lurian-Bertani plates containing 5 pg/ml 
phleomycin (Eurogentech) and used for generating various ex- 
pression vectors. 
The expression vector pRc/Ac (Mayer et al., 1994) was used 
as a source of domain C5 cDNA connected to the BM-40 signal 
peptide. The 0.4-kb insert was released with HindII/NotI, puri- 
fied by agarose gel electrophoresis and inserted into the poly- 
linker region of pCEP-Sh 3‘ next to its CMV promoter to obtain 
vector pCEP-Sh/Ac. Human embryonic kidney cells which con- 
stitutively express the EBNA-1 protein from Epstein-Barr virus 
(H293 EBNA, Invitrogen) were used for transfection (Nischt et 
al., 1991) in order to increase the replication rate of the plasniid. 
The initial selection of transfected cells was accomplished in the 
presence of 25 pg/ml phleomycin which was then reduced to 
7 pg/ml during the phase of collecting serum-free culture 
medium. 
Construction of C5 mutant expression vectors. Mutants 
were generated from the pCEP-Sh/Ac vector by PCR with Vent 
polymerase (Biolabs) following the supplier’s instruction. Com- 
mercially obtained oligonucleotides (Pharmacia) FP-Not 5’- 
CTGGATCCGGCCTTGCCGGCC for the 3‘end and FP-Hind 
5’-GAAGCTGGGTACCAGCTG for the 5’end together with 
two overlapping oligonucleotides (see below) matching the re- 
gion designated for mutation were used to produce two overlap- 
ping subfragments of C5 which were then purified by agarose 
gel electrophoresis. A mixture of these fragments was denatured, 
annealed and used as a template to obtain a full-length cDNA 
by five cycles of PCR. Subsequent addition of the terminal prim- 
ers (FP-Not, FP-Hind) was followed by 25 cycles of PCR to 
amplify the product. These PCR products were restricted with 
Hind11 and NotI, purified on a Sephacryl S-400 micro spin col- 
umn following the supplier’s protocol (Pharmacia) and inserted 
into the HinmIVNotI-restricted pCEP-Sh vector and cloned in 
E. coli. The correct insertion and mutation was then verified by 
cycle sequencing on a 373A DNA sequencer (Applied Bio- 
systems). 
The following primers were used for introducing single 
amino acid mutations (mutated nucleotides are underlined) and 
neutral mutations which introduced additional restriction sites : 
primer 1, 5’-GATATATGCAAGTTGCCGAAAGACGAAGG- 
ACCCTGCAGGG ; primer 2, 5’-CGGCAACTTGCATATATC ; 
primer 3, S’-GGAACTTGCAGGGCTTTCATA~TTAA~TGG- 
TACTATGATCCAA ; primer 4,5’-TATGAAAGCCCTGCAAC- 
TTCCTT ; primer 5 ,  5’-ACACCAAAAGCTGTGCACGATT- 
CGTGTATGGAGGTTGTGGTGG ; primer 6, 5’-GCACAGCT- 
TTTGGTGTTTG ; primer 7, S’GCAGGGCTAGGATATTAA- 
AATGGTACTATGATCC ; primer 8, 5’-AATATmAGCCCT- 
GCAAGTTCC. 
These primers were used with pCEP-Sh/Ac as template to 
produce mutant T + P  (primers 1 and 2), mutant D+A (primers 
3 and 4) and mutant W + V  (primers 5 and 6). Two amino acid 
substitutions were introduced with the template of mutant D +A 
using the primer combinations 1 and 2 (mutant T+P/D-+A)  
and 7 and 8 (mutant D-+A/F+R). Two different triple amino 
acid substitutions were constructed using the mutant T+P/ 
D+A template and primers 5 and 6 (mutant T-+P/D-+A/ 
and 2 (mutant T-+P/D+A/F-+R). H293-EBNA cells were then 
used for transfections with the mutated vectors as described 
above. 
Purification and sources of proteins and proteases. Re- 
combinant C5 and its mutants were initially purified from 
serum-free culture medium (0.5-1 1) of transfected cells on 
DEAE-cellulose (Mayer et al., 1994). None of recombinant 
products bound to the column and were dialysed against 0.2 M 
NH,HCO, then lyophilized. They were then passed over a re- 
verse-phase C18 column equilibrated in 0.1 % trifluoroacetic 
acid (Mayer et al., 1991) and could be eluted as distinct peaks 
in a narrow range of the acetonitrile gradient (0-70%). Recom- 
binant mouse nidogen was prepared as described (Fox et al., 
1991). Reference protease inhibitors used were aprotinin (Trasy- 
lolR, Bayer AG) and the thrombin inhibitor rhodniin (Friedrich et 
al., 1993) kindly provided by Dr W. Bode (Martinsried). Trypsin 
treated with N-a-tosyl-L-phenylalanine chloromethane (Wor- 
thington) or of sequencing grade (Boehringer Mannheim) and 
thrombin (Boehringer Mannheim) were purchased and human 
leucocyte elastase was a gift of Dr H. P. Nick (Ciba-Geigy, 
Basel). 
Surface plasmon resonance assay. Assays were performed 
in a BlAcore apparatus equipped with CM 5 chips from Phar- 
macia Biosensor (Fagerstam et al., 1992). Trypsin was immobi- 
lized on the CM 5 chip via amine coupling procedure. After 
activation of the carboxymethylated dextran layer by addition of 
35 pl of a mixture of 0.05 M N-hydroxysuccinimide and 0.2 M 
N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide at a flow rate 
of 5 pl/min, 50  p1 of trypsin solution in 0.1 M sodium acetate 
pH 4.5 (1 mg/ml) was added. Residual activated carboxyl groups 
of the chip were saturated by reaction with 35 pl 1 M ethanol- 
amine pH 8.5. This resulted in 4800 resonance units of immobi- 
lized trypsin, which corresponds to a surface concentration of 
about 5 ng/mm2. Binding assays were performed in 10 mM 
Hepes pH 7.4, 150 mM NaCI, 3.4 mM EDTA and 0.05% BIA- 
core P20 surfactant at a flow rate of 5 pl/min. Soluble ligands 
were applied in the concentration range 3 - 100 pM, depending 
on the binding constants. This resulted in signals of about 200- 
1100 resonance units. Kinetic constants were calculated from 
the association phase and the dissociation phase, respectively, 
using BTAevaluation software version 2.1. The binding curves 
were fitted according to the one-to-one model A+B = AB. Ex- 
periments with buffer alone revealed a small baseline drift indi- 
cating some leakage of the immobilized trypsin. This constant 
drift was used to correct both the association and dissociation 
curves. 
Protease inhibition assays. Nidogen (200 pg/ml) was dis- 
solved i n  0.05 M Tris/HCI pH 7.4, 0.1 M NaC1, 2 mM CaCIZ 
and incubated with individual proteases for 4-24 h at 37°C 
(2-20 pg/ml). Protease inhibitors were added to the proteases 
at 5- or 100-fold molar excess and incubated for 1 h at 37°C 
prior to mixing with nidogen. Aliquots were then taken for ex- 
amination of fragment patterns by electrophoresis (Mayer et al., 
The peptide substrate carbobenzoxy-valyl-glycyl-arginine 4- 
nitrilanilide acetate (ChromozymeR TRY, Boehringer Mann- 
heim) was used for the determination of inhibitory constants 
( K , ) .  A 10-pI aliquot of trypsin in 0.1 niM HC1 (2.5 pg/ml) was 
incubated ( 5  min, 22°C) with 10 p1 inhibitor (2.5-20 pg/ml) 
dissolved in 0.1 M Tris/HCl pH 7.4, 20 mM CaCI,. This short 
incubation prevented interference by trypsin autolysis but still 
allowed sufficient binding of the inhibitor. After addition of 
780 p1 0.1 M Tris/HCI pH 7.4, 20 mM CaClz containing 10 or 
20 pl substrate (10 mM), protease activity was monitored at 
405 nm and 22°C in a Shimadzu UV-260 spectrophotometer for 
1994). 
W+V) and the mutant D+A/F+R template and primers 1 5-10 min. K,  values were then determined’accorjiiig to the Mi- 
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Fig. 1. Ribbon diagram of recombinant domain C5 and identification 
of the four residues changed by site-directed mutations. These resi- 
dues (T2886, D2889, F2890, W2907) are shown with their side chains. 
Arrows denote the substitutions introduced. P1 denotes the scissile 
amide bond between Arg2888 (Pl) and Asp2889(PI’). The structure is 
based on NMR data (Zweckstetter et al., 1996). 
chaelis-Menton equation for competitive inhibition (Todhunter, 
1979) : 
Analytical methods. Concentrations of protein solutions 
were determined on a LC 3000 amino acid analyzer (Biotronik) 
after hydrolysis (6 M HCI, 16 h, llO°C). SDS gel electrophore- 
sis and ELISA followed standard protocols. The rabbit antisera 
against domain C5 have been previously described (Mayer et al., 
1994). Electrospray ionisation mass spectrometry was performed 
following established methods (Covey et al., 1988; Fenn et al., 
1989). 
Molecular modelling. The model molecular dynamics cal- 
culations of C5 were performed in the presence of NMR con- 
straints with the program X-PLOR 3.1 (Briinger, 1993) using 
protocols described previously (Zweckstetter et al., 1996; Holak 
et al., 1989). Starting structures were the final structures ob- 
tained by Zweckstetter et al. (1996). The 4/y angles of the P4 
to P4’ residues of C5 were set to the values found in aprotinin 
in the present calculations, with tight boundaries of ?loo. No 
violations of distance constraints larger than 0.06 nm were ob- 
served in the new structures. Surface potentials were calculated 
using DELPHI (Gilson and Honig, 1987) and displayed using 
the program GRASP (Nicholls et al., 1991). 
RESULTS 
Production and properties of site-directed mutants of do- 
main C5. Recombinant domain C5 from the collagen VI a3 
chain (positions 2869-2943) was previously shown to lack in- 
hibitory activity for several proteases including some with tryp- 
sin-like specificity (Mayer et al., 1994). This was interpreted to 
be due to the presence of unfavorable residues in the P3, P1’ 
and P2’ position of the binding loop and a bulky Trp in the 
adjacent p strand (Fig. 1) which are atypical for Kunitz inhibitor 
modules. We have now prepared seven C5 mutants including a 
T+P (P3), a D+A (Pl’), a F+R (P2’) and a W+V mutation 
(Fig. 1) in order to increase the similarity of C5 to the trypsin 
inhibitor aprotinin (Laskowski and Kato, 1980) at several critical 
sites. They were designed to introduce either one, two or three 
amino acid substitutions into C5 (Table 1). These mutants will 
be referred to in the following by the one-letter code for the 
amino acids exchanged. All mutants could be produced in an 
episomal expression system which ensured their proper folding 
Table 1. Identification of the C5 mutants used and analysis of their 





T+P 8 341 5 7  8 341.5 
D+A 8 301.54 8 301.7 
w+v 8 258.48 8 257.6 
T+P/D+A 8 297.55 8 298.0 
D + A/F+ R 8 310.55 8 308.8 
T + PJD + AIW +V 8 210.48 8 209.8 
T + P/D + AlF+ R 8 306.57 8 306.2 
I I  I I 
lo- ’  10-2 I 0-3 lo-‘ 
Antibody dilution 
Fig. 2. ELISA binding of an antiserum against domain C5 to various 
C5 mutants. Immobilized antigens were domain C5 (O), mutant W+V 
(m), mutant T+P  (A), mutant D+A (V), mutant T+P/D+A (O), 
mutant D+A/F+R (O),  mutant T+P/D+A/F+R (A), mutant T+P/ 
D+AiW+V (V), aprotinin (0) and serum albumin as a negative 
control (+). 
and secretion from transfected mammalian cells. They were 
purified in two chromatographic steps and obtained in 1 -2-mg 
yields from 1 1 serum-free culture medium. 
Electrospray mass spectrometry demonstrated a molecular 
mass for the mutants consistent with the formation of three di- 
sulfide bridges (Table 1). The purified mutants showed a major 
band of about 8-10 kDa in SDS gel electrophoresis (data not 
shown but see Fig. 4) as found before for recombinant C5 
(Mayer et al., 1994). As a conformational probe, we used anti- 
bodies against C5 which, as previously shown, failed to bind 
unfolded C5 (Mayer et al., 1994). ELISA titration demonstrated 
no or only little differences between the mutants and CS (Fig. 2) 
indicating no substantial loss of conformational epitopes. Aprot- 
inin, however, which has only about 50% sequence identity, did 
not bind the antibodies. 
Binding to trypsin in surface plasmon resonance assay. This 
assay allows kinetic measurements in real time and the determi- 
nation of Kd values based on association and dissociation rates 
(Fagerstam et al., 1992). Domain CS and its single-site mutants 
T + P  and W+V showed no binding to immobilized trypsin 
indicating a Kd distinctly larger than 1 pM. All other mutants 
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Fig. 3. Overlay plot of sensorgrams of the interaction of C5 mutants 
and aprotinin with trypsin obtained by surface plasmon resonance 
assay. The mutants are identified by the letters as described in Table 1. 
The ligands were injected at about 100s. The dissociation phase started 
at about SOOs, except for aprotinin (330s). 
Table 2. Kinetic parameters and dissociation equilibrium constants 
(Kd)  of the binding of C5 mutants to immobilized trypsin. Binding 
way meavurcd by surtace plasmon resonance at the Concentrations indi- 
cdted 
Soluble ligand Concn k,,, k,,,, Kd 
S-' nM M~ I s-l I.IM 
c5 7 no binding 
T+P 12 no binding 
W + V  6 no binding 
D+A 0.06-4.1 3.0X104 7 .5X10 ' 250 
T+P/D +A 14.1 1.6X104 1.8x10-' I I  
D + AIF+R 10.3 2.5 X 10' 7.5 X 2.8 
T+PID+A/W+V 13.1 8.6 X lo" 4.0 X 10 " 0.046 
T+P/D+AIF+R 2.6 1.2 x 10' 2.7 x lo-" 0.023 
Aprotinin 3.3 1.1 x 10' 3.4X 1O-"  0.031 
showed a comparably fast association which reached saturation 
levels after 2.5-5 min but differed considerably in the speed of 
dissociation as illustrated by some typical sensorgrams in Fig. 3. 
This was confirmed by a quantitative determination of rate con- 
stants (Table 2) which showed only a threefold difference in the 
lowest and higheat association rates but a high variation over 
three orders of magnitude for the dissociation rates. The latter 
variation results in a similar range of affinities for the mutants 
(Table 2). The affinity was lowest (K', = 250 nM) for mutant 
D + A  but increased 25-100-fold by adding a second substitu- 
tion in the mutants T+P/D-+A and D+A/F+R. A further 
increase by two orders of magnitude was achieved by adding a 
third mutation to mutant T+P/D+A in one of two other posi- 
tions (mutants T+P/D+ A N  +V and T+ P/D +A/F+R). 
These triple mutants had rate constants and affinities indistin- 
guishable from those of aprotinin within the limits of analytical 
error. 
Inhibitory properties of C5 mutants for proteases. The inhibi- 
tory activity of C5 mutants was analyzed with several proteases 
to which they were added in 5-fold or 100-fold molar excess 
prior to the addition of nidogen as a high-molecular-mass, highly 
protease-sensitive substrate. The digestion patterns were then 
examined at different time points by SDS gel electrophoresis 
(Fig. 4). No inhibition of trypsin was observed for domain C5 
and mutants W + V  or T + P  at either inhibitor/protease ratio 
while complete inhibition occurred with mutants T + P / t + A /  
A 



















Fig.4. Effects of C5 mutants on trypsin (A) and leucocyte elastase 
(B) cleavage of nidogen. Digestion was carried out for 4 h at 37°C and 
examined by SDS gel clectrophoresis. Lane 1, undigested nidogen con- 
trol; lane 2, protease digest of nidogen without inhibitor; lanes 3-1 1, 
identical digests to lane 2 in the presence of C5 (lane 3), mutant W + V  
(lane 4), mutant T+P (lane S), mutant D+A (lane 6), mutant T+P/ 
D+A (lane 7), mutant D+A/F+R (lane 8), mutant T+P/D+A/ 
W+V (lane 9), mutant T+P/D+A/F+R (lane 10) and aprotinin (lane 
11). Inhibitors at 5-fold (trypsin) or 100-fold (elastase) molar excess 
were incubated with the proteases prior to the addition of nidogen. The 
gels were calibrated with marker proteins denoted by their molecular 
mass (in kDa). The extra band around 8 kDa in lanes 3-11 is due to 
the added inhibitors. 
W+V and T+P/D+A/F+R and aprotinin at 5-fold inhibitor 
excess. Mutants D+A, T+P/D-+A and D+A/F+R showed 
only partial inhibition which increased in accordance with their 
K,, values (Fig. 4A). 
Leucocyte elastase with a K, of about 10 pM for aprotinin 
(Lestienne and Bieth, 1978) was used as a second, low-affinity 
protease to analyze the activity of the mutants in the nidogen 
cleavage assay (Fig. 4B).  Aprotinin showed a distinct but only 
partial inhibition which is explained by its concentration being 
only fourfold higher than the K,, value. A similar activity was 
only observed for mutant T + P / D + A N + V .  Mutants T+P/ 
D+A/F-+R and T+P/D+A showed weaker activities and 
none was found for C5 or any other mutants. Thus the inhibitory 
activities of the mutants show distinct differences between 
leucocyte elastase and trypsin (Fig. 4A). A further difference 
was noted for thrombin, which readily cleaves nidogen into a 
100-kDa and a 50-kDa fragment (Mayer et al., 1993). When 
used at the same concentrations as in the leucocyte elastase 
assay neither aprotinin, C5 nor any of its mutants showed inhibi- 
tory activity (data not shown). Cleavage could, however, be 
completely inhibited by a fivefold molar excess of rhodniin. 
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Table 3. Inhibitory constants (Ki )  of C5 mutants for trypsin cleavage 
of a small peptide substrate. Values were determined at substrate con- 
centrations of 0.125 mM and 0.25 mM using 1.3 nM trypsin and inhibi- 
tors in the concentration range 3.8-30.1 nM. 
Inhibitor K,  at [S]: 
0.125 mM 0.25 mM 
nM 
Table 4. Reactive-site loop conformation of domain C5 and aproti- 
nin. The data of aprotinin were taken from Deisenhofer and Steigemann 
(1975) and those of domain C5 from Zweckstetter et al. (1996). Aster- 
isks denote in C5 residues which were changed in the various mutants. 
For definition of the backbone angles @ty, see Branden and Tooze 
(1991) page 8. 
Loop Domain C5 Aprotinin 
posi- 
tion residue (ply angles residue 4 1 ~  angles 
C5 
T + P  
w + v  
D + A  
T + PID + A 
D + AIF + R 
T + PID + A/W + V 













P3 Thr * 
P2 CYS 
PI ‘4% 
PI’ Asp * 
P2‘ Phe * 
P3’ Ile 
deg. 
5 8 5  61 1 2 2  6 
8.55 21 30+ 3 
7 6 2  21 31222 
-97 t 34/-160? 10 
-1142 51 4 2 2  8 




















A small peptide substrate with a single trypsin cleavage site 
was used for comparison of K, and Kd values. Two substrate 
concentrations were chosen which were 1.5 or 3 times higher 
than the K,, value of the reaction (0.0824 mM), and showed 
identical K, values within the limits of analytical error except 
with mutant D+A (Table 3). The data demonstrated no activity 
for domain C5 and its mutants T + P  and W+V. The K, values 
for the other mutants and aprotinin agreed within one order of 
magnitude with the equilibrium dissociation constants deter- 
mined by the surface plasmon resonance assay (Tables 2 and 3). 
This demonstrated that direct binding and inhibitory capacity 
are determined by the dissociation rate constants. This was also 
consistent with the nature of the Lineweaver-Burk plots (not 
shown) which demonstrated competitive inhibition for all active 
C5 mutants. 
Molecular modelling of the C5 binding loop. The present 
NMR structure calculation of C5 was basically performed in an 
analogous manner to that previously described (Zweckstetter et 
al., 1996). The only difference was the introduction of additional 
constraints for dihedral angles in the binding loop which simu- 
lated its conformation in a complex with trypsin. Two assump- 
tions were made:first, that the binding loop was less variable 
upon binding to trypsin; second, that the conformation of the 
binding loop was canonical, i.e. the 4I1y angles of P4 to P4’ 
residues of C5 were set to those found in aprotinin (Table 4). 
The best superposition of P5 to P5’ residues of the adjusted C5 
and aprotinin in a simulated or actual complex with trypsin is 
shown in Fig. 5.  It can be seen from Fig. 5 that it was possible 
to adjust the conformation of the backbone of the binding loop 
to the canonical conformation of aprotinin without significant 
violation of NMR constraints. In addition, most of the side 
chains in such an adjusted loop pointed in the same directions 
as those of aprotinin. The notable exception was Phe (P2’ site), 
for which the x, angle was 180” relative to that of the Arg in 
P2’ of aprotinin. In this conformation, the aromatic ring clashes 
with residues Gln192 and Gly193 of trypsin (for example, the 
distance C5 Phe Cy to trypsin Gln192 C was only 0.1 nm). If 
the x, angle were to be set to the value found in P2’(Arg) of 
aprotinin, a number of NOEs between protons of the ring of Phe 
and neighbouring or distant residues of C5 would be violated. 
These NOEs must be removed during the calculations for the 
ring to flip into the xI orientation found in aprotinin. Even if 
such NOE contacts did not exist i n  the hypothetical complex of 
Fig.5. Superposition of the binding loops and part of the first /3 strand of the modelled structure of domain C5 and of aprotinin in a 
complex with trypsin. The structure of C5 is shown in red and its residues are denoted in black. The aprotinin structure is muIticolored showing 
carbons in green, nitrogens in blue oxygens in red and disulfide bonds in yellow. The p strand shows the surrounding of the tryptophan (W) which 
was subjected to mutation in C5 (W+V). 
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Fig.6. Electrostatic potential surfaces of domain C5 (A) and aprotinin (B). The inhibitors are viewed from the top of their binding loops and a 
few critical positions are marked (P), Blue regions represent positive, red negative and white neutral potentials. 
trypsin-C5, the hydrophobic Phe at P2’ in C5 does not permit 
hydrogen bonding found i n  aprotinin, where imino protons of 
the side chain of Arg make bonds to oxygen donors of trypsin. 
DISCUSSION 
Domain C5 at the C-terminus of human type VI collagen 
a3(VI) chain corresponds to a Kunitz-type module and some 
additional residues at the C-terminal (Chu et al., 1990). As 
shown by immunological analyses, this domain is immediately 
released probably by proteolytic processing after assembly and 
secretion of type VI collagen has been accomplished (Mayer et 
al., 1994). The released form persists in the circulation but could 
not be detected in the extracellular matrix. Recombinant domain 
C5 was further shown to lack inhibitory activity for trypsin and 
several other proteases despite having an Arg in the P1 position 
of the binding loop. The biological function of domain C5 there- 
fore remains to be established but the possibility remains that it 
could be an inhibitor of proteases specialized for certain pur- 
poses. 
The lack of predicted inhibitory function led us to examine 
the structural basis for this observation by site-directed mutagen- 
esis. The mutations were restricted to four residues based on 
sequence comparisons (Mayer et al., 1994) which retrospec- 
tively were also in agreement with predictions derived from the 
X-ray structure of domain C5 (Arnoux et al., 1995). Three mut- 
ations were localized i n  the binding loop and one in the adjacent 
p strand (Fig. 1). Single mutations (T+P, D q A ,  W+V),  ex- 
cept for D2889-A, showed no significant increase in affinity 
compared to domain C5 in direct binding and inhibition assays 
with trypsin. A combination of two mutations (T+P/D+A, 
D+A/F+R) or of three mutations (T+P/D+A/F+R, T+P/  
D+A/W+V) showed in each case a considerable increase in 
affinity by about two orders of magnitude. Yet it was surprising 
that two different substitutions in the triple mutants, either in the 
binding region (F+R) or the p strand (W+V), produced the 
same effects. Thus a very limited change in the sequence identity 
of domain C5 and aprotinin, which does not exceed 50%, caused 
a crucial change i n  the functional potential. 
Most of the effects caused by mutations of C5 can now be 
interpreted in terms of the tertiary structure in solution which 
was recently completed (Zweckstetter et al., 1996). This demon- 
strated that the 57-residue core of domain C5 has the characteris- 
tic fold of all members of Kunitz-type protease inhibitors 
(Fig. 1). The NMR study, however, also showed a highly dy- 
namic structure for C5 where about 44% of the core residues can 
exist in multiple conformations. Such sites included a substantial 
portion of the binding loop which is defined by the P3, P2, P I ,  
PI‘, P2’ and P3’ sites around the scissile peptide bond between 
P1 and Pl’ (see Table 4) and three of the four positions chosen 
for mutations (D-A, F+R, W j V ) .  A similar variability of 
the binding loop was also found in NMR studies of other prote- 
ase inhibitors such as aprotinin (Wagner et al., 1987; Otting et 
al., 1993), leech-derived tryptase inhibitor (Muhlhahn et al., 
1994), the trypsin inhibitor from squash seeds (Holak et al., 
1989) and eglin c (Hyberts et al., 1992). Thus lack of trypsin 
inhibition by domain C5, despite a favorable Arg at the P1 posi- 
tion, cannot be accounted for by conformational variability and 
very likely arises by the specific nature of the side chains of a 
few critical residues within or close to the binding loop. This is 
particularly evident for Asp at the P1’ site of domain C5, which 
is usually occupied by Ala or Gly in other inhibitors. This ex- 
poses a negative charge on the surface of C5 not found in aproti- 
nin (Fig. 6) which should be incompatible with the negatively 
charged binding cleft of trypsin and, in addition, causes steric 
interference with His57 of trypsin. These predictions were veri- 
fied with the D+A mutant, which was the only single C5 sub- 
stitution yielding a measurable trypsin binding activity. Thus 
Asp seems to be the most crucial residue in the binding loop 
which determines the inhibitory activity for trypsin-like prote- 
ases. 
Other substitutions worked only in the context of an existing 
D + A  mutation. These included a T+P mutation at the P3 site 
which caused a 25-fold improvement in activity. The Pro at the 
aprotinin P3 site forms a main-chain hydrogen bond to Gly216 
of trypsin whereas, if it is changed to Thr in C5, it probably 
forms hydrogen bonds to a spatially adjacent Cys in C5 as 
shown by NMR analysis at pH 2.7. This is in agreement with 
the crystal structure of domain C5, which demonstrated that the 
direction of the carbonyl oxygen of Thr is opposite to that of 
Pro in aprotinin and is dependent on a different chirality of the 
adjacent disulfide bridge (Arnoux et al., 1995). Apparently, the 
formation of either an inter- or intra-molecular hydrogen bond 
as a consequence of the rotation of the carbonyl group is the 
most likely interpretation of our experimental observation. 
A more complex situation seems to exist for the Phe at the 
P2’ site of C5, which, when changed to Arg as in aprotinin, also 
improves binding activity. The aromatic ring seems to be fixed 
into a hydrophobic pocket consisting of F2890, W2907 and 
(32909 (Fig. 5) .  Furthermore, the presence of a hydrophobic resi- 
due at the P2‘ site should show severe steric hindrance with 
Gln192 and Gly193 of trypsin and abolish side-chain hydrogen 
bonds of the Arg imino protons to oxygen donors of trypsin. In 
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order to relieve these constraints, the side chain of F2890 needs 
to flip into the x, orientation as found in aprotinin. This seems, 
however, not possible in domain C5 because of unfavorable van 
der Waals contacts with the bulky ring of W2907, which is 
located on the neighbouring /3 strand just below the binding loop 
(Figs 1 and 5). This dualism provides a perfect explanation as 
to why two different third mutations (F+R, W+V) to the 
T+P/D-+A mutant structure cause the same improvement in 
trypsin inhibitory activity which is then equivalent to aprotinin. 
Aprotinin is also a weak inhibitor of leucocyte elastase (Les- 
tienne and Bieth, 1978), in spite of a Lys in the P1 position 
which, when changed to Val, causes an increase in activity by 
five orders of magnitude (Wenzel et al., 1986). Several of the 
C5 mutants also showed inhibitory activity but it did not fully 
correlate with the relative increases in trypsin affinity when 
compared in a semiquantitative assay. Most remarkable was the 
identical activity observed for mutant T+P/D+A/W+V and 
aprotinin while both mutants T+P/D+A/F+R and T+P/ 
D+A had a similar lower activity. This indicates distinct differ- 
ences in the binding sites of the two proteases which remain to 
be fully determined. 
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